United Kingdom

Background and Aims: • NAFLD is the most common liver condition worldwide and is directly linked to chronic excess calorie consumption, lack of physical activity and overweight/obesity. • NAFLD can progress to non-alcoholic steatohepatitis (NASH). Incidence of NASHrelated end stage liver disease is increasing. • Concurrent with an increasing prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) and sarcopenic obesity are rising. • There is growing evidence of a causal link between sarcopenia and the development of NAFLD. • A very low calorie diet (VLCD) has been postulated as a possible solution for NAFLD, however, there are concerns that a VLCD may induce further reduction of skeletal muscle mass (SMM). Methods: • 30 patients with advanced NAFLD were recruited to an 8-12 week VLCD (~800 kcal/day) using meal replacement products (Optifast, Nestlè Health Science). • 11 patients opted to extend the VLCD intervention beyond 8 weeks up to 12. • Anthropometrics, body composition, blood tests (liver enzymes, lipid profile, glucose, HbA1c, insulin), liver stiffness, Quality of life, and cardiovascular disease risk were measured at baseline and after the VLCD intervention. • Bioelectrical impedance analysis was used to determine body composition; fat mass (FM), fat-free mass (FFM) and skeletal muscle mass (SMM). • Anthropometrics and blood tests were also measured at weeks 1, 3, 5, 7 (and at weeks 9 and 11). • Given the intense caloric restriction, patients were not encouraged to partake in heavy exercise during a VLCD. Results: • Of the 45 patients approached to take part in this study, 30 consented to enrol. This study was fully recruited at a single site within 6 months and 27/30 retained post VLCD. • 68% of patients reached the weight loss target of 10%; mean weight loss was 13kg (3-39), equivalent to 11% (3-26). • Weight loss through an 8-12 week VLCD significantly improved (Table 1); -BMI and body composition -liver health (liver enzymes and liver stiffness) -cardiometabolic disease risk (blood pressure and QRISK2) -There was a moderate positive correlation between weight loss and change in SMM (r=0.444, p=0.034). -QOL and weight related symptom measure (WRSM) significantly improved from 44±26 to 55±20 (p=0.001) and 43±30 to 31±23 (p=0.039), respectively. Conclusions • Despite previous concerns that a VLCD may exacerbate sarcopenic characteristics, the VLCD intervention did not significantly affect SMM, but induced efficient weight loss. • it may be beneficial to encourage continuation of daily physical activity during the VLCD and an increase in physical activity/exercise after completion of the VLCD, to maintain long-term weight-loss and FFM/SMM.

ISTRC 2021 - International Sarcopenia Translational Research Conference

The effect of a very low calorie diet on body composition in patients with non-alcoholic fatty liver disease

vlcd

weight loss

nafld

Welcome to the inaugural International Sarcopenia Translational Research Conference.  “Where Worlds Meet” – the event brings together a broad range of researchers and practitioners in a truly interdisciplinary forum, covering discovery science through to clinical practice.

###### Explore the programme handbook [here](https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fonline.flippingbook.com%2Fview%2F850225452%2F&data=04%7C01%7CEleanor.Lockhart%40newcastle.ac.uk%7Cd440f87ca7184685a56708d926629eaf%7C9c5012c9b61644c2a91766814fbe3e87%7C1%7C0%7C637583027282147963%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=xoB29O8tJ6VXAjUDTNCCKo9SyoSo12aak0dJX3wEalg%3D&reserved=0).



Access to this event requires a registration. Please email Eleanor Lockhart at sarcconf@ncl.ac.uk if you have any questions regarding your registration. 

poster

Introduction: Disability leads to immobilisation associated with profound changes in body composition. The potential risks involved with these changes i.e. loss of lean tissue mass (LM) vs. gain in fat mass (FM) in body composition have implications for the health of the disabled individuals. The investigation of sarcopenic obesity is important in populations with disabilities as they lead to metabolic disorders and concomitant diseases that aggravate the neurological picture. Purpose: The primary outcomes of the study were to investigate indicators of sarcopenic obesity and correlations with obesity and body mass indices. Secondary outcomes were investigation of sarcopenia indices and the relationship with sarcopenic obesity in people with neurological disabilities (strokes, spinal cord injuries, traumatic brain injuries). Methods – Material: The study Sarcopenic Obesity in NeuroDisabled Subjects (Acronym: SarcObeNDS) is an observational study of hospitalized patients and controls (90 and 30 respectively), aged 60.00 ± 14.22, who were examined with full body absorption dual energy absorption measurements in body composition measurements. Sarcopenic obesity was assessed with the indicators: fat mass%, and fat mass index to height 2 (Kg / m2 ) and sarcopenia with skeletal muscle index (peripheral muscle mass to height 2 (Kg / m2 ) - SMI. The study is registered in the international database ClinicalTrials.gov with unique number: NCT03863379. Results: A statistically significant difference was found in body mass index (26.70 ± 4.54 vs. 24.27 ± 4.55, p = 0.012) and in BMD (7.18 ± 0.95 vs. 6.00 ± 1.13, p <0.001). No statistical significance was found in total fat (%) (p = 0.793) and fat mass index to height2 (p = 0.143). A strong positive statistically significant correlation was found between BMI and total fat index (%) and between BMI and total fat mass (r= 0.616 p <0.001 vs. r = 0.728 p <0.001 and r = 0.420 p <0.001 vs. r = 0.868 p <0.001, respectively) in controls and people with disabilities. Conclusion: At the clinical level, the recognition of these diseases will prevent metabolic disorders in these vulnerable populations.

Sarcopenic Obesity in Neurodisabilities: The SarcObeNDS study

Background: This study examined the impact of sarcopenia on clinical outcome in patients who underwent infrainguinal bypass surgery or major lower limb amputation (MLLA). Methods: Patients undergoing infra-inguinal bypass and MLLA in 2016-2018 were included in this retrospective analysis. Sarcopenia was identified by CT of muscle area at L3 vertebral. Primary outcome was overall survival, analysed using Cox regression. Secondary outcomes for bypass included ipsilateral MLLA, length of hospital stay, myocardial infarction and surgical-site infection. For the MLLA cohort we included stump infection and breakdown. These were analysed using Fisher’s test (categorical), Mann-Whitney U test (non-parametric) and t-test (parametric). Results: 216 patients (116 bypass, 100 MLLA) were included. 14/116 (12%) of bypass patients and 13/100 (13%) of MLLA patients were sarcopenic. Age, other co-morbidities, and laboratory tests were similar in those with and without sarcopenia. Overall survival was worse for sarcopenic patients (HR for death 5.8; 95%CI 1.8-19.1; p=0.001) in the bypass cohort, however, this was not observed in the MLLA cohort (HR 1.29; 95%CI 0.23-2.62; p=0.7). MLLA occurred more frequently in patients with sarcopenia (7/14 [50%] vs 23/102 [23%]; p=0.046). There was no difference in other secondary outcomes in either cohort. Conclusion: In the cohort of patients undergoing infrainguinal lower limb bypass, sarcopenia defined using L3 muscle area was significantly associated with overall mortality and MLLA, however sarcopenia was not associated with worse survival in the MLLA group. Sarcopenia and frailty may be a key factor in stratifying those who should undergo an amputation-first approach to CLTI.

The influence of sarcopenia on lower limb bypass & major lower limb amputation outcomes

Background: Mitochondrial dysfunction is a potential therapeutic target to improve skeletal muscle function, but the contribution of mitochondrial dysfunction to impaired skeletal muscle performance in older people remains unclear. The aim of this analysis was to test the association between measures of skeletal muscle mitochondrial function and physical performance in older people. Methods: We analysed data from the Allopurinol in Functional Impairment trial. Participants aged 65 and over, who were unable to walk 400 m in 6 min, underwent 31P magnetic resonance spectroscopy of the calf after exercise at baseline and at 20 weeks follow up. The phosphocreatine recovery half-life time (t1/2) was derived as a measure of mitochondrial function. Participants undertook the 6-min walk test and the Short Physical Performance Battery. Muscle mass measured using the Akern 101 bio-impedance analysis system. Bivariate correlations and multivariable regression analyses were conducted to determine associations between t1/2 and baseline factors. Results: One hundred and seventeen participants underwent baseline 31P magnetic resonance spectroscopy, mean age 80.4 years (SD 6.0); 56 (48%) were female. Mean 6-min walk was 291 m (SD 80), mean SPPB score was 8.4 (SD 1.9); t1/2 correlated significantly with Short Physical Performance Battery score (r = 0.22, P = 0.02) but not with 6-min walk distance (r = 0.10, P = 0.29). In multivariable linear regression, muscle mass and total body weight, but not t1/2, were independently associated with Short Physical Performance Battery score and with 6-min walk distance. Change in t1/2 was not significantly associated with change in Short Physical Performance Battery score (r = 0.03, P = 0.79) or with change in 6-min walk distance (r = −0.11, P = 0.28). Conclusions: Muscle mass, but not phosphocreatine recovery time, was consistently associated with Short Physical Performance Battery score and 6-min walk distance in older people with functional impairment.

Is Mitochondrial Function Measured by 31p Magnetic Resonance Spectroscopy Associated With Physical Performance in Older People With Functional Impairment?

Background: Sarcopenia, defined as the age-related loss of muscle mass and strength, is a major health problem. The condition is common, affecting between 5 and 10% of communitydwelling people aged over 65. It is a major cause of multiple adverse outcomes for older people including falls, fractures, hospital admission, prolonged length of stay, need for care and reduced survival. The objectives of the LACE trial were to determine the efficacy of leucine and perindopril in improving physical function, muscle mass and quality of life in older people diagnosed with sarcopenia. Methods: LACE was a placebo-controlled, parallel group, double-blind, randomised two-by-two factorial trial. Participants: Adults aged ≥70 years with low muscle strength and low muscle mass, without contraindications to ACE inhibitors and without known diagnosis-specific skeletal myopathy recruited from 14 UK centres. Interventions: Eligible participants were randomised 1:1 to 4mg oral perindopril or matching placebo, and separately randomised 1:1 to oral leucine powder 2.5g or matching placebo powder taken thrice daily with meals. Interventions were given for 12 months. Outcome measures: The primary outcome was the between-group difference in the Short Physical Performance Battery score (measured at baseline, 6 and 12 months). Secondary outcomes included grip strength, quadriceps strength, six-minute walk distance, appendicular muscle mass measured by dual x-ray absorptiometry and quality of life (EQ5D tool). All adverse events and falls were recorded. Outcomes were analysed using repeated measures mixed models, adjusted for baseline values, age, sex and minimisation variables. Prespecified subgroup analyses for the primary outcome were also conducted for age, sex and baseline protein intake. An initial test for treatment interaction showed no evidence of interaction and thus the perindopril vs placebo and leucine vs placebo comparisons were conducted separately. Recruitment: We screened 320 people and randomised 145 participants, mean age 79 (SD 6) years; 78 (54%) were women and the mean SPPB was 7.0 (SD 2.4). Figure 1 shows the CONSORT diagram for recruitment. Conclusion: Perindopril did not improve physical performance, muscle mass or quality of life in older people with sarcopenia in this trial.

Effect of perindopril on physical performance, muscle mass and quality of life in older people with sarcopenia: Results from the LACE randomised controlled trial

Background: Sarcopenia, defined as the age-related loss of muscle mass and strength, is a major health problem. The condition is common, affecting between 5 and 10% of communitydwelling people aged over 65. It is a major cause of multiple adverse outcomes for older people including falls, fractures, hospital admission, prolonged length of stay, need for care and reduced survival. The objectives of the LACE trial were to determine the efficacy of leucine and perindopril in improving physical function, muscle mass and quality of life in older people diagnosed with sarcopenia. Methods: LACE was a placebo-controlled, parallel group, double-blind, randomised two-by-two factorial trial. Participants: Adults aged ≥70 years with low muscle strength and low muscle mass, without contraindications to ACE inhibitors and without known diagnosis-specific skeletal myopathy recruited from 14 UK centres. Interventions: Eligible participants were randomised 1:1 to 4mg oral perindopril or matching placebo, and separately randomised 1:1 to oral leucine powder 2.5g or matching placebo powder taken thrice daily with meals. Interventions were given for 12 months. Outcome measures: The primary outcome was the between-group difference in the Short Physical Performance Battery score (measured at baseline, 6 and 12 months). Secondary outcomes included grip strength, quadriceps strength, six-minute walk distance, appendicular muscle mass measured by dual x-ray absorptiometry and quality of life (EQ5D tool). All adverse events and falls were recorded. Outcomes were analysed using repeated measures mixed models, adjusted for baseline values, age, sex and minimisation variables. Prespecified subgroup analyses for the primary outcome were also conducted for age, sex and baseline protein intake. An initial test for treatment interaction showed no evidence of interaction and thus the perindopril vs placebo and leucine vs placebo comparisons were conducted separately. Recruitment: We screened 320 people and randomised 145 participants, mean age 79 (SD 6) years; 78 (54%) were women and the mean SPPB was 7.0 (SD 2.4). Figure 1 shows the CONSORT diagram for recruitment. Conclusion: Leucine did not improve physical performance, muscle mass or quality of life in older people with sarcopenia in this trial.

Effect of leucine supplementation on physical performance, muscle mass and quality of life in older people with sarcopenia: Results from the LACE randomised controlled trial

Background: Anorexia of ageing is common but often not assessed in clinical practice despite the availability of simple tools such as the four-item Simplified Nutritional Appetite Questionnaire (SNAQ)1. Anorexia of ageing is associated with altered dietary pattern, weight loss and malnutrition, potentially contributing to the development of sarcopenia through loss of muscle mass. However, the association between appetite and muscle strength is less clear. Methods: Cross sectional observational study of community dwelling adults aged over 60 years, attending outpatient appointments in one hospital. Appetite was assessed using SNAQ; muscle strength by handgrip strength with a Jamar dynamometer and standard protocol. The association between appetite (SNAQ score between 5 and 20) and grip strength was assessed in unadjusted and adjusted continuous analyses. Results: We observed an association between poorer appetite and lower muscle strength in community dwelling older adults, independent of sex. This association was not robust when accounting for effects of age and comorbidity. Poor appetite may be associated with low muscle strength prior to older age and comorbidities but further investigation is needed. Appetite is simple to assess in older people using SNAQ and may prove useful in earlier identification of individuals at risk of developing sarcopenia.

Poor appetite is associated with lower muscle strength in community dwelling older adults

Introduction: • Physical activity in older adults has been shown to play a key role in the prevention of Sarcopenia1 . • There are barriers to physical activity in older adults, in particular environmental and access to resources2 . • The corona virus pandemic (COVID-19) caused the UK government to introduce measures to limit the spread of the virus such as: local & national lockdowns, self-isolation & shielding for vulnerable adults > 70 yrs. of age. • Few studies to date have quantitatively investigated the impact of the COVID-19 restrictions on physical activity in older adults. Methods: • Physical activity was measured in 14 volunteers (mean age ± SD: 62 ± 8) on two occasions; before restrictions (08/11/2018 - 02/03/2020) and during restrictions (10/11/2020 – 14/05/2021). • Participants wore a wrist-worn tri-axial accelerometer for 7 days. Minutes per day spent in moderate-vigorous physical activity (MVPA) and mean acceleration per hour (mg/h), were derived from recordings. • The average ratio of MVPA from the two assessments was used to assess changes in MVPA & differences in mean acceleration were analysed using a correlation analysis. Conclusions: • In this small population no significant changes in PA due to covid restrictions were observed. • More data from a wider age range should be collected to fully address the question of what impact covid restrictions have had on PA in older persons.

Assessing changes in physical activity in community dwelling older adults before and after COVID-19 restrictions in the United Kingdom

Introduction: 
1) Frailty – a risk factor of mortality and morbidity post-surgery
2) Currently available frailty scores – only assess one or selected few of
frailty’s components
3) Aims – to assess the feasibility of comprehensively measuring frailty of
elective cardiac surgery patients
Methods:
Study period – 01/12/2018 to 30/09/2020, follow-up until 31/12/2020
1) Patients – all cardiac surgery patients older than 70 years
2) Comprehensive frailty assessment in the pre-assessment clinic
3) NEFS – 1 point each, 11 in total, 4 points = frail
Results:
201 consecutively recruited – 36 excluded (incomplete assessment)
165 patients – 63 (38.2%) frail, 102 (61.8%) non-frail
Conclusion:
1) Feasible to comprehensively evaluate cardiac surgery patients’ frailty
using the North East frailty score
2) NEFS independently predicts post-cardiac surgery outcomes
3) Further validation is required
4) NEFS has the potential to facilitate the heart team to better risk
stratify patients and help patients make informed decision


Premium content

The effect of a very low calorie diet on body composition in patients with non-alcoholic fatty liver disease

Next from ISTRC 2021 - International Sarcopenia Translational Research Conference

Sarcopenic Obesity in Neurodisabilities: The SarcObeNDS study

Similar lecture

Clinical and functional characteristics of sarcopenic vs non sarcopenic older women living in different settings

Stay up to date with the latest Underline news!

PRESENTATIONS

CONFERENCES

COMPANY

RESOURCES